bioAffinity Technologies

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BIAF and other ETFs, options, and stocks.

About BIAF

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. 

CEO
Maria Zannes
CEOMaria Zannes
Employees
57
Employees57
Headquarters
San Antonio, Texas
HeadquartersSan Antonio, Texas
Founded
2014
Founded2014
Employees
57
Employees57

BIAF Key Statistics

Market cap
4.38M
Market cap4.38M
Price-Earnings ratio
-0.07
Price-Earnings ratio-0.07
Dividend yield
Dividend yield
Average volume
585.06K
Average volume585.06K
High today
$0.77
High today$0.77
Low today
$0.6121
Low today$0.6121
Open price
$0.76
Open price$0.76
Volume
430.52K
Volume430.52K
52 Week high
$13.50
52 Week high$13.50
52 Week low
$0.6121
52 Week low$0.6121

Stock Snapshot

As of today, bioAffinity Technologies(BIAF) shares are valued at $0.67. The company's market cap stands at 4.38M, with a P/E ratio of -0.07.

As of 2026-07-13, bioAffinity Technologies(BIAF) stock has fluctuated between $0.61 and $0.77. The current price stands at $0.67, placing the stock +10.1% above today's low and -12.5% off the high.

The bioAffinity Technologies(BIAF)'s current trading volume is 430.52K, compared to an average daily volume of 585.06K.

In the last year, bioAffinity Technologies(BIAF) shares hit a 52-week high of $13.50 and a 52-week low of $0.61.

In the last year, bioAffinity Technologies(BIAF) shares hit a 52-week high of $13.50 and a 52-week low of $0.61.

BIAF News

TipRanks 6d
bioAffinity Technologies’ CyPath Lung Test Sees Rapid Growth

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

TipRanks 6d
BioAffinity Technologies’ CyPath Lung diagnostic sales double in Q2

bioAffinity Technologies (BIAF) announced continued acceleration in commercial sales for CyPath Lung, its noninvasive lung cancer diagnostic, with more than 200...

People also own

Based on the portfolios of people who own BIAF. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.